Pricing Log in Create free account

Black Diamond Therapeutics, Inc. (BDTX) vs Neuraxis, Inc. (NRXS)

Black Diamond Therapeutics, Inc. and Neuraxis, Inc. are both Biotechnology companies. Black Diamond Therapeutics, Inc. and Neuraxis, Inc. are of similar size ($100.0M and $97.2M). Black Diamond Therapeutics, Inc. has the higher net margin (0.00% vs −159.0%) and the higher return on invested capital (0.00% vs 0.00%). Across the 12 metrics below, Black Diamond Therapeutics, Inc. leads on 9 and Neuraxis, Inc. on 3.

Valuation

Metric BDTX NRXS Biotechnology median
P/E n/m n/m 8.50
P/S n/m 17.55 9.71
P/B 1.03 13.86 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.23 n/m 0.64
EV/Sales n/m 16.00 9.21
Earnings yield (43.60%) (10.13%) (33.15%)
Free cash flow yield (33.25%) (6.20%) (25.50%)

Profitability

Metric BDTX NRXS Biotechnology median
Gross margin 0.00% 85.56% 65.16%
Operating margin 0.00% (144.51%) 0.00%
Net margin 0.00% (159.01%) 0.00%
Free cash flow margin 0.00% (106.10%) 0.00%
Return on equity (37.21%) (153.96%) (56.36%)
Return on assets (29.21%) (98.96%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BDTX NRXS Biotechnology median
Revenue growth (TTM) — 65.22% 6.02%
EPS growth (last fiscal year) 130.71% 22.13% 30.26%
Revenue growth, 5-year CAGR — 13.08% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BDTX NRXS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.28 3.04 4.72
Net debt to EBITDA (10.01) 0.64 0.96

Dividend

Metric BDTX NRXS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric BDTX NRXS Biotechnology median
Market cap 99.97m 97.19m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack